IC-P2-145: Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study

2008 ◽  
Vol 4 ◽  
pp. T64-T64
Author(s):  
Wiesje M. van der Flier ◽  
Jasper Sluimer ◽  
Femke Bouwman ◽  
Hugo Vrenken ◽  
Marinus A. Blankenstein ◽  
...  
2010 ◽  
Vol 31 (5) ◽  
pp. 758-764 ◽  
Author(s):  
Jasper D. Sluimer ◽  
Femke H. Bouwman ◽  
Hugo Vrenken ◽  
Marinus A. Blankenstein ◽  
Frederik Barkhof ◽  
...  

2008 ◽  
Vol 4 ◽  
pp. T547-T547
Author(s):  
Wiesje M. Van der Flier ◽  
Jasper Sluimer ◽  
Femke H. Bouwman ◽  
Hugo Vrenken ◽  
Marinus A. Blankenstein ◽  
...  

Radiology ◽  
2008 ◽  
Vol 248 (2) ◽  
pp. 590-598 ◽  
Author(s):  
Jasper D. Sluimer ◽  
Wiesje M. van der Flier ◽  
Giorgos B. Karas ◽  
Nick C. Fox ◽  
Philip Scheltens ◽  
...  

Neurology ◽  
2008 ◽  
Vol 70 (Issue 19, Part 2) ◽  
pp. 1836-1841 ◽  
Author(s):  
J. D. Sluimer ◽  
H. Vrenken ◽  
M. A. Blankenstein ◽  
N. C. Fox ◽  
P. Scheltens ◽  
...  

2010 ◽  
Vol 31 (9) ◽  
pp. 1601-1605 ◽  
Author(s):  
Gabriela Spulber ◽  
Eini Niskanen ◽  
Stuart MacDonald ◽  
Oded Smilovici ◽  
Kewei Chen ◽  
...  

Author(s):  
Y. Wu ◽  
A. D. Smith ◽  
H. Refsum ◽  
Timothy Kwok

Abstract Background and Objectives A randomized placebo-controlled trial found a significant negative interaction between aspirin and B vitamins in cognitive functioning in older people with mild cognitive impairment (MCI). To validate this finding, we pooled data of this trial with that of a similar B-vitamin trial (VITACOG) to examine the effectiveness of B vitamins and their interactions with aspirin in improving global cognitive functioning and slowing brain atrophy in older people with MCI. Design Pooled post-hoc analyses of two randomized placebo-controlled trials. Participants In total, 545 older people with MCI were included in the study. Intervention Placebo or B-vitamin supplements (vitamin B12, folic acid with or without vitamin B6) for 24 months. Measurements The primary outcome was the Clinical Dementia Rating scale-global score (CDR-global). The secondary outcomes were CDR-sum of box score (CDR-SOB), memory Z-score, executive function Z-score, and whole brain atrophy rate. Results 71 (26.2%) and 83 (30.3%) subjects in the active and placebo group respectively were aspirin users. Overall, B vitamins reduced whole brain atrophy rate significantly (P = 0.003), but did not have significant effect on CDR-global, CDR-SOB, memory and executive function. Aspirin use had significant negative interaction effects on B vitamins in CDR-global and CDR-SOB (Beta = 0.993, P = 0.038, and Beta = 0.583, P = 0.009, respectively), but not in memory or executive function Z-scores. Among aspirin non-users, B-vitamin group subjects had more favourable changes in CDR-global and CDR-SOB (P = 0.019 and 0.057, respectively). B vitamins significantly slowed brain atrophy in aspirin non-users (P = 0.001), but not in aspirin users, though the interaction term was not significant (Beta = 0.192, P = 0.276). Conclusion In older people with MCI, B vitamins had significantly favourable effects on global cognitive functioning and whole brain atrophy rate in those who were not taking aspirin, but not in aspirin users.


2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
C. Guevara ◽  
K. Bulatova ◽  
G. J. Barker ◽  
G. Gonzalez ◽  
N. Crossley ◽  
...  

In multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), the absence of surrogate endpoints makes clinical trials long and expensive. We aim to determine annualized whole-brain atrophy rates (a-WBAR) in idiopathic Parkinson’s disease (IPD), MSA, and PSP. Ten healthy controls, 20 IPD, 12 PSP, and 8 MSA patients were studied using a volumetric MRI technique (SIENA). In controls, the a-WBAR was0.37%±0.28(CI 95% 0.17–0.57), while in IPD a-WBAR was0.54%±0.38(CI 95% 0.32–0.68). The IPD patients did not differ from the controls. In PSP, the a-WBAR was1.26%±0.51(CI 95%: 0.95–1.58). In MSA, a-WBAR was1.65%±1.12(CI 95%: 0.71–2.59). MSA did not differ from PSP. The a-WBAR in PSP and MSA were significantly higher than in the IPD group (p=0.004andp<0.001, resp.). In PSP, the use of a-WBAR required one-half of the patients needed for clinical scales to detect a 50% reduction in their progression. In MSA, one-quarter of the patients would be needed to detect the same effect. a-WBAR is a reasonable candidate to consider as a surrogate endpoint in short clinical trials using smaller sample sizes. The confidence intervals for a-WBAR may add a potential retrospective application for a-WBAR to improve the diagnostic accuracy of MSA and PSP versus IPD.


2004 ◽  
Vol 35 (03) ◽  
Author(s):  
S Schnaudigel ◽  
T Ugur ◽  
F Kruggel ◽  
HJ Mentzel ◽  
C Fitzek ◽  
...  

NeuroImage ◽  
2014 ◽  
Vol 86 ◽  
pp. 203-211 ◽  
Author(s):  
Jiyang Jiang ◽  
Perminder Sachdev ◽  
Darren M. Lipnicki ◽  
Haobo Zhang ◽  
Tao Liu ◽  
...  

2016 ◽  
Vol 12 ◽  
pp. P518-P518
Author(s):  
Xiaowei Song ◽  
Hui Guo ◽  
Ryan C.N. D'Arcy ◽  
William Siu ◽  
John Diggle ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document